Celon Pharma (WAR:CLN) Beneish M-Score: 0.00 (As of Jun. 25, 2026)


WAR:CLN Celon Pharma SA WAR:CLN
57 GF Score
Price zł19.52
GF Value zł22.51
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Beneish M-Score?

Celon Pharma WAR:CLN -2.30% 57 Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus rates WAR:CLN with a GF Score™ of 57/100 and a GF Value™ of zł22.51 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Celon Pharma ranks worse than 109769.37% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Celon Pharma's Beneish M-Score or its related term are showing as below:

During the past 11 years, the highest Beneish M-Score of Celon Pharma was 1.03. The lowest was -4.72. And the median was -2.49.


Celon Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Beneish M-Score Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.85 -2.75 -2.34 1.03 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

WAR:CLN vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Beneish M-Score falls into.


WAR:CLN
57GF Score
Celon Pharma SA WAR:CLN
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Celon Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was zł0.0 Mil.
Revenue was zł0.0 Mil.
Gross Profit was zł0.0 Mil.
Total Current Assets was zł0.0 Mil.
Total Assets was zł457.5 Mil.
Property, Plant and Equipment(Net PPE) was zł0.0 Mil.
Depreciation, Depletion and Amortization(DDA) was zł0.0 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.0 Mil.
Total Current Liabilities was zł63.3 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.0 Mil.
Net Income was zł-79.4 Mil.
Gross Profit was zł0.0 Mil.
Cash Flow from Operations was zł23.9 Mil.
Total Receivables was zł0.0 Mil.
Revenue was zł177.5 Mil.
Gross Profit was zł114.4 Mil.
Total Current Assets was zł0.0 Mil.
Total Assets was zł543.8 Mil.
Property, Plant and Equipment(Net PPE) was zł0.0 Mil.
Depreciation, Depletion and Amortization(DDA) was zł51.9 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.0 Mil.
Total Current Liabilities was zł66.9 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0) / (0 / 177.549)
= / 0
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(114.378 / 177.549) / (0 / 0)
=0.644205 /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0 + 0) / 457.46) / (1 - (0 + 0) / 543.796)
=1 / 1
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 177.549
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(51.859 / (51.859 + 0)) / (0 / (0 + 0))
=1 /
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 0) / (0 / 177.549)
= / 0
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 63.269) / 457.46) / ((0 + 66.899) / 543.796)
=0.138305 / 0.123022
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-79.363 - 0 - 23.853) / 457.46
=-0.225628

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Celon Pharma (WAR:CLN) has a Beneish M-Score of 0.00 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #999999 out of 911 companies in the Drug Manufacturers industry.
Is Celon Pharma's Beneish M-Score too high?
Celon Pharma's current Beneish M-Score is 0.00. Based on the distribution chart, Celon Pharma ranks #999999 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Celon Pharma has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #999999 out of 911 companies for Beneish M-Score. This places Celon Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Celon Pharma and its competitors. Celon Pharma's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.51, compared to a current price of zł19.52 — trading 13.3% below its estimated fair value. The current Beneish M-Score is 0.00. Celon Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.52 is trading 13.3% below its estimated GF Value™ of zł22.51. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Beneish M-Score: 0.00
  • GF Value™: zł22.51 vs. price of zł19.52 (13.3% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score

Get the complete analysis for WAR:CLN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.52
Price
zł22.51
GF Value